Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab added to atezolizumab plus carboplatin and etoposide for untreated extensive-stage small cell lung cancer
NL-OMON54967Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tiragolumab, atezolizumab, carboplatin and etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by Roche. Primary endpoints: Progression-free survival and Overall survival. Started Aug 2020; status: active, not recruiting.
02
Drugs
tiragolumabatezolizumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON54967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54967.